HRP20220653T1 - Sastavi koji sadrže oslabljeni virus newcastleske bolesti i postupci uporabe za liječenje neoplazije - Google Patents

Sastavi koji sadrže oslabljeni virus newcastleske bolesti i postupci uporabe za liječenje neoplazije Download PDF

Info

Publication number
HRP20220653T1
HRP20220653T1 HRP20220653TT HRP20220653T HRP20220653T1 HR P20220653 T1 HRP20220653 T1 HR P20220653T1 HR P20220653T T HRP20220653T T HR P20220653TT HR P20220653 T HRP20220653 T HR P20220653T HR P20220653 T1 HRP20220653 T1 HR P20220653T1
Authority
HR
Croatia
Prior art keywords
ndv
cancer
cell
optionally
heterologous polynucleotide
Prior art date
Application number
HRP20220653TT
Other languages
English (en)
Croatian (hr)
Inventor
Hong Jin
Danielle CARROLL
Matthew Mccourt
Xing Cheng
Mark GALINSKI
Original Assignee
Medimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Limited filed Critical Medimmune Limited
Publication of HRP20220653T1 publication Critical patent/HRP20220653T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/768Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17Newcastle disease virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18111Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18111Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18111Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18111Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20220653TT 2013-09-03 2014-09-02 Sastavi koji sadrže oslabljeni virus newcastleske bolesti i postupci uporabe za liječenje neoplazije HRP20220653T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361873039P 2013-09-03 2013-09-03
EP18188565.8A EP3508209B1 (en) 2013-09-03 2014-09-02 Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia

Publications (1)

Publication Number Publication Date
HRP20220653T1 true HRP20220653T1 (hr) 2022-06-24

Family

ID=51492938

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20190250TT HRP20190250T1 (hr) 2013-09-03 2014-09-02 Pripravci koji sadrže ublaženi virus newcastleske bolesti i postupci uporabe za liječenje neoplazije
HRP20220653TT HRP20220653T1 (hr) 2013-09-03 2014-09-02 Sastavi koji sadrže oslabljeni virus newcastleske bolesti i postupci uporabe za liječenje neoplazije

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20190250TT HRP20190250T1 (hr) 2013-09-03 2014-09-02 Pripravci koji sadrže ublaženi virus newcastleske bolesti i postupci uporabe za liječenje neoplazije

Country Status (25)

Country Link
US (2) US10519426B2 (OSRAM)
EP (3) EP3041490B1 (OSRAM)
JP (2) JP6557234B2 (OSRAM)
KR (2) KR102310692B1 (OSRAM)
CN (2) CN106163532B (OSRAM)
AU (2) AU2014317215C1 (OSRAM)
CA (1) CA2922071C (OSRAM)
CY (2) CY1121993T1 (OSRAM)
DK (2) DK3508209T3 (OSRAM)
EA (2) EA202191926A3 (OSRAM)
ES (2) ES2914577T3 (OSRAM)
HK (1) HK1231393A1 (OSRAM)
HR (2) HRP20190250T1 (OSRAM)
HU (1) HUE042382T2 (OSRAM)
LT (2) LT3041490T (OSRAM)
ME (1) ME03345B (OSRAM)
MX (2) MX367768B (OSRAM)
PL (2) PL3041490T3 (OSRAM)
PT (2) PT3041490T (OSRAM)
RS (2) RS58332B1 (OSRAM)
SI (2) SI3508209T1 (OSRAM)
SM (2) SMT202200214T1 (OSRAM)
TR (1) TR201902073T4 (OSRAM)
TW (1) TWI653334B (OSRAM)
WO (1) WO2015032755A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016217B1 (ru) 2005-12-02 2012-03-30 Маунт Синай Скул Оф Медсин Химерные вирусы, представляющие неприродные поверхностные белки, и их применение
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
WO2014158811A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
CN106163532B (zh) * 2013-09-03 2019-12-31 免疫医疗有限公司 以减毒的新城疫病毒为特征的组合物和用于治疗瘤形成的使用方法
SG11201607130RA (en) 2014-02-27 2016-09-29 Viralytics Ltd Combination method for treatment of cancer
CN107847610B (zh) * 2015-04-28 2022-02-01 塞维卡有限责任公司 基于piv5的扩增病毒样颗粒
CN109312309B (zh) 2016-01-08 2024-04-02 雷普利穆内有限公司 工程化的病毒
EP3246410A1 (en) * 2016-05-19 2017-11-22 Klinikum rechts der Isar der Technischen Universität München Vsv/ndv hybrid viruses for oncolytic therapy of cancer
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
KR101964610B1 (ko) * 2017-03-13 2019-04-03 대한민국 신규한 종양용해성 바이러스 및 이의 용도
JOP20190256A1 (ar) * 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN107254450A (zh) * 2017-07-20 2017-10-17 扬州大学 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法
CN108486279A (zh) * 2017-09-21 2018-09-04 山东省农业科学院家禽研究所 一种基于荧光定量pcr技术检测鸽新城疫病毒的方法
EP3552608A1 (en) * 2018-04-09 2019-10-16 Rapo Yerape B.H. Ltd Increased activity of oncoloytic newcastle disease virus
WO2020014591A1 (en) * 2018-07-13 2020-01-16 Icahn School Of Medicine At Mount Sinai Apmv and uses thereof for the treatment of cancer
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease
CN110859968A (zh) * 2019-11-21 2020-03-06 四川安可康生物医药有限公司 激活对肿瘤的系统免疫反应的基因生物药物
EP4121453A2 (en) * 2020-03-20 2023-01-25 Orna Therapeutics, Inc. Circular rna compositions and methods
CN115197949A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途
US20220396809A1 (en) * 2021-06-03 2022-12-15 University Of Guelph Engineered newcastle disease virus vector and uses thereof
KR20250144435A (ko) * 2023-02-06 2025-10-10 사이안백 엘엘씨 변형된 piv5 백신 벡터: 제조 및 사용 방법
WO2025116613A1 (ko) * 2023-11-29 2025-06-05 주식회사 카브 재조합 뉴캣슬병 바이러스 벡터를 포함하는 암 치료용 약제학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7724558B1 (en) * 1999-03-19 2010-05-25 Nec Corporation Magnetic signal transmission line
ATE451835T1 (de) * 1999-09-24 2010-01-15 Mayo Foundation Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
US20090208495A1 (en) 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
EP2987856B1 (en) * 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
WO2014158811A1 (en) * 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
CN106163532B (zh) * 2013-09-03 2019-12-31 免疫医疗有限公司 以减毒的新城疫病毒为特征的组合物和用于治疗瘤形成的使用方法
CN109099045A (zh) * 2018-10-30 2018-12-28 浙江斯泰新材料科技股份有限公司 防松锁固型螺钉

Also Published As

Publication number Publication date
PT3508209T (pt) 2022-05-27
EA202191926A3 (ru) 2022-01-31
AU2019204419B2 (en) 2021-09-02
EA202191926A2 (ru) 2021-10-29
AU2014317215A8 (en) 2016-04-21
DK3508209T3 (da) 2022-05-30
JP2019193662A (ja) 2019-11-07
PL3041490T3 (pl) 2019-05-31
MX2016002771A (es) 2016-09-06
JP2016533749A (ja) 2016-11-04
TR201902073T4 (tr) 2019-03-21
US11471499B2 (en) 2022-10-18
SI3508209T1 (sl) 2023-01-31
CN106163532B (zh) 2019-12-31
AU2014317215C1 (en) 2019-09-12
EP3041490B1 (en) 2018-11-14
EP3508209B1 (en) 2022-03-09
HUE042382T2 (hu) 2019-06-28
MX367768B (es) 2019-09-05
JP6557234B2 (ja) 2019-08-07
AU2014317215B2 (en) 2019-03-28
AU2014317215A1 (en) 2016-04-14
LT3508209T (lt) 2022-06-10
HK1225643B (en) 2017-09-15
JP6862500B2 (ja) 2021-04-21
ES2914577T3 (es) 2022-06-14
WO2015032755A1 (en) 2015-03-12
CN111944767A (zh) 2020-11-17
HRP20190250T1 (hr) 2019-05-31
TWI653334B (zh) 2019-03-11
EP3508209A1 (en) 2019-07-10
ES2708755T3 (es) 2019-04-11
CA2922071A1 (en) 2015-03-12
RS63291B1 (sr) 2022-06-30
KR20210048605A (ko) 2021-05-03
US20160208222A1 (en) 2016-07-21
MX2019010364A (es) 2019-10-07
CY1121993T1 (el) 2020-10-14
HK1231393A1 (zh) 2017-12-22
RS58332B1 (sr) 2019-03-29
CY1126790T1 (el) 2024-12-13
SMT202200214T1 (it) 2022-07-21
LT3041490T (lt) 2019-02-25
CN106163532A (zh) 2016-11-23
EA039404B1 (ru) 2022-01-24
KR20160047570A (ko) 2016-05-02
TW201606079A (zh) 2016-02-16
KR102310692B1 (ko) 2021-10-12
DK3041490T3 (en) 2019-03-04
US20200181581A1 (en) 2020-06-11
PL3508209T3 (pl) 2022-06-13
KR102285894B1 (ko) 2021-08-04
CA2922071C (en) 2022-05-03
SMT201900094T1 (it) 2019-02-28
US10519426B2 (en) 2019-12-31
PT3041490T (pt) 2019-02-06
SI3041490T1 (sl) 2019-03-29
EA201690425A1 (ru) 2016-08-31
AU2019204419A1 (en) 2019-07-11
ME03345B (me) 2019-10-20
EP3041490A1 (en) 2016-07-13
EP4101457A1 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
HRP20220653T1 (hr) Sastavi koji sadrže oslabljeni virus newcastleske bolesti i postupci uporabe za liječenje neoplazije
JP2019193662A5 (OSRAM)
HUS2500003I1 (hu) Módosított IX-es faktor, valamint készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez
HRP20201066T1 (hr) Anti-pvrig antitijela i postupci uporabe
Belmonte-Beitia et al. Effective particle methods for Fisher–Kolmogorov equations: theory and applications to brain tumor dynamics
JP2016533749A5 (OSRAM)
MX2018014993A (es) Uso de endonucleasa cpf1 para modificaciones de genoma de planta.
GT201700200A (es) Composiciones y métodos para activar la señalización dependiente del "estimulador del gen de interferon"
PH12017501040A1 (en) Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
MX2015012891A (es) Composiciones y metodos de variantes de inhibidor tisular de la metaloproteinasa tipo tres (timp-3).
MX2021014663A (es) Il-23a y tnf-alfa orientados y compuesto y sus usos.
TW201613956A (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
MY174248A (en) Targeted/immunomodulatory fusion proteins and methods for making same
EA201890960A1 (ru) Натуральные киллеры и клетки ilc3 и их применение
DK3229831T3 (da) Fremgangsmåder og sammensætninger til reduktion af vækst, migration og invasivitet af hjernecancerstamceller og forbedring af overlevelsen for patienter med hjernetumorer
MX377210B (es) Vacuna para enfermedad de newcastle y de bursitis infecciosa (nd-ibd) en vector de hvt mejorada.
EP3592787A4 (en) MICROGEL PARTICLES FOR USE IN 3D PRINTING AND 3D CELL GROWTH MEDIA AND ASSOCIATED COMPOSITIONS, SYSTEMS AND PROCESSES
PH12018500151A1 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
MX2019013240A (es) Elementos reguladores de plantas y sus usos.
PH12018501162A1 (en) Targeted mutagenesis of tobacco berberine bridge enzyme-like nucleic acids
MX370800B (es) Elementos reguladores de plantas y sus usos.
NZ752275A (en) Compositions and methods for enhancing the stability of transgenes in poxviruses
CR20220377A (es) Elementos reguladores vegetales y sus usos
NZ748198A (en) Plant regulatory elements and uses thereof
Kazemi et al. The effect of endurance training on MiR-155 expression, STAT3 gene expression, and interleukin 6 protein in mice with breast cancer